Have a hemoglobin level less than 12.5g/dL (females) or 13.0g/dL (males)
Dosing schedule is individualized based on clinical response and treatment goals Duration & Monitoring Program Duration Most patients participate for a minimum of 3 months, with many remaining on therapy for 6 to 12 months or longer depending on weight loss goals, metabolic health, and long-term maintenance plan Ongoing Monitoring Regular physician follow-up to assess progress, adjust dosing, monitor side effects, reinforce lifestyle modifications, and optimize long-term outcomes Results Expected Results Gradual, clinically meaningful weight reduction, decreased hunger and food noise, improved portion control, and improvements in metabolic health including blood glucose regulation and insulin sensitivity Results Timeline Appetite reduction often begins within the first several weeks, while meaningful weight loss develops progressively over several months

Importantly, NICE does not recommend placing individuals with binge eating disorder on calorie-restricted diets as a standalone treatment, as this may worsen binge frequency
Most adults who have taken GLP-1 drugs say they took them to treat a chronic condition including diabetes or heart disease (62%), while about four in ten say they took them primarily to lose weight
We reasoned that the enhanced response in knockout islets was attributed to a compensatory enhancement in GLP-1R signaling that has been previously described in various GIPR knockout models 10,21,22
These BPC-157 erectile dysfunction effects for nerve protection are relevant for improving male sex organ performance by preserving nerve integrity and functionality